- Home
- EM vs CHRS Comparison
EM vs CHRS Comparison
Compare EM & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EM
- CHRS
- Stock Information
- Founded
- EM 2017
- CHRS 2010
- Country
- EM China
- CHRS United States
- Employees
- EM N/A
- CHRS N/A
- Industry
- EM Other Consumer Services
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- EM Consumer Discretionary
- CHRS Health Care
- Exchange
- EM Nasdaq
- CHRS Nasdaq
- Market Cap
- EM 281.5M
- CHRS 84.2M
- IPO Year
- EM 2021
- CHRS 2014
- Fundamental
- Price
- EM $1.14
- CHRS $0.73
- Analyst Decision
- EM Hold
- CHRS Buy
- Analyst Count
- EM 1
- CHRS 3
- Target Price
- EM $1.25
- CHRS $4.68
- AVG Volume (30 Days)
- EM 68.2K
- CHRS 1.3M
- Earning Date
- EM 08-21-2025
- CHRS 08-07-2025
- Dividend Yield
- EM N/A
- CHRS N/A
- EPS Growth
- EM N/A
- CHRS N/A
- EPS
- EM N/A
- CHRS N/A
- Revenue
- EM $259,541,587.00
- CHRS $272,251,000.00
- Revenue This Year
- EM $3.30
- CHRS N/A
- Revenue Next Year
- EM $5.26
- CHRS $106.56
- P/E Ratio
- EM N/A
- CHRS N/A
- Revenue Growth
- EM N/A
- CHRS 19.87
- 52 Week Low
- EM $0.50
- CHRS $0.66
- 52 Week High
- EM $1.17
- CHRS $2.43
- Technical
- Relative Strength Index (RSI)
- EM 62.65
- CHRS 41.45
- Support Level
- EM $1.13
- CHRS $0.72
- Resistance Level
- EM $1.16
- CHRS $0.77
- Average True Range (ATR)
- EM 0.03
- CHRS 0.04
- MACD
- EM 0.00
- CHRS 0.00
- Stochastic Oscillator
- EM 75.00
- CHRS 13.65
About EM Smart Share Global Limited
Smart Share Global Ltd is a consumer tech company providing mobile device charging services through an extensive online and offline network in China. It provides service through power banks, placed in POIs operated by location partners, such as entertainment venues, restaurants, shopping centers, hotels, transportation hubs, and public spaces. Geographically, the company generates revenue from the PRC. The company has two segments, the mobile device charging segment and the PV business segment. The company generates the majority of its revenue from the mobile device charging segment.
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.